Wnt/β-catenin signaling pathway
In the canonical arm, Wnt ligands engage FZD and LRP5/6; Dishevelled-centered signaling inhibits the APC–AXIN–GSK3 destruction complex, stabilizing β-catenin for nuclear partnering with TCF/LEF transcription factors. The axis operates across development, stem-cell niches, intestinal renewal, and many cancers, while non-canonical (PCP, Ca²⁺) branches and crosstalk with TGF-β, RTK–PI3K, Hippo, etc. are common—separate protein abundance from TCF-dependent transcriptional activity.
1. Key targets
Core nodes (overview)
- Wnt ligands
- • Secreted palmitoylated glycoproteins
- • Engage FZD + LRP5/6 to nucleate signalosomes
- Frizzled (FZD)
- • 7TM receptor family (FZD1–10)
- • Partners with LRP5/6 in functional complexes
- β-catenin (CTNNB1)
- • Co-activator; also adherens junction pool
- • Canonical arm: stabilization enables TCF/LEF programs
- GSK3β
- • Destruction-complex kinase driving β-catenin phosphorylation
- • Extensive crosstalk with PI3K–AKT, etc.
Upstream & membrane initiation
- Wnt secretion: PORCN, WLS (GPR177)
- LRP5/6 co-receptors; RSPO–LGR amplification; RNF43/ZNRF3 E3s
- Extracellular antagonists: DKK, SFRP, WIF, Kremen, etc.
Downstream transcription & readouts
- TCF7 / LEF1 / TCF7L2 complexes with β-catenin
- Targets: AXIN2, MYC, CCND1, MMP7… (context-dependent)
- TOPFlash/SuperTOP and p-LRP6-style mechanistic readouts
Supplement: Wnt/β-catenin–related targets (gene symbols)
Below the overview, HGNC-style symbols group ligands/secretion, receptors/co-receptors, cytosolic signalosome, destruction complex, adherens pools, nuclear transcription, RSPO–LGR–E3 modules, extracellular antagonists, canonical targets, non-canonical branches, and crosstalk nodes. Validate isoforms and cellular context with HGNC/UniProt and papers.
Ligands & palmitoylation/secretion
Wnt ligands (secreted glycoproteins)
WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16
Secretion & palmitoylation machinery
PORCN, WLS, GPR177
Receptors & co-receptors
Frizzled receptors
FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, FZD10
LRP5/6 co-receptors & membrane initiation
LRP5, LRP6
Non-canonical context receptors (representative)
Often discussed for PCP, Ca²⁺, or β-catenin-independent arms.
ROR1, ROR2, RYK, PTK7
Cytosolic signalosome & PCP crosstalk
Dishevelled & proximal regulation
DVL1, DVL2, DVL3, FRAT1, FRAT2
Casein kinases & stepwise phosphorylation
CSNK1A1, CSNK1D, CSNK1E
PCP module proteins (crosstalk)
VANGL1, VANGL2, PRICKLE1, PRICKLE2, PRICKLE3, CELSR1, CELSR2, CELSR3
Destruction complex & tankyrase axis
Destroyosome scaffold
APC, APC2, AXIN1, AXIN2
GSK3, β-TrCP & ubiquitin targeting
GSK3A, GSK3B, BTRC
Tankyrase–Axin axis
TNKS1, TNKS2
Adherens junction pool
β-catenin & adherens junction pool
Membrane vs cytosolic/nuclear pools compete for available CTNNB1.
CTNNB1, CDH1, CTNNA1, CTNNA2, CTNND1, CTNNBIP1
Nuclear transcription machinery
TCF / LEF transcription factors
TCF7, LEF1, TCF7L1, TCF7L2
Enhancer-complex cofactors
BCL9, BCL9L, PYGO1, PYGO2, CBY1
Chromatin & co-regulators (representative)
CREBBP, EP300, SMARCA4, TLE1, TLE2, TLE3, TLE4
RSPO–LGR & membrane E3s
R-spondin–LGR amplification
RSPO1, RSPO2, RSPO3, RSPO4, LGR4, LGR5, LGR6
Membrane E3s & feedback (RNF43/ZNRF3)
RNF43, ZNRF3
Extracellular antagonists
DKK–Kremen, SFRPs, WIF
DKK1, DKK2, DKK3, DKK4, KREMEN1, KREMEN2, SFRP1, SFRP2, SFRP3, SFRP4, SFRP5, WIF1
Canonical downstream targets
Canonical target genes (common readouts)
AXIN2, LEF1, MYC, CCND1, MMP7, VEGFA, BMP4, DKK1, NOTUM, ASCL2, OLFM4
Non-canonical branches (representative)
PCP / Daam–Rho (representative)
DAAM1, DAAM2, RAC1, RHOA, ROCK1, ROCK2, MAPK8, MAPK9
Wnt/Ca²⁺–NFAT context (representative)
CAMK2A, CAMK2B, PPP3CA, PPP3CB, NFATC1, NFATC2, NFATC3
Crosstalk nodes
Crosstalk: Hippo, RTK–PI3K, TGF-β, etc.
Separate β-catenin protein levels from TCF-dependent transcription.
YAP1, WWTR1, TEAD1, TEAD4, PIK3CA, AKT1, SMAD2, SMAD3, SMAD4, NOTCH1, GLI1, GLI2
2. Suggested experimental readouts
Pick phospho sites and stimulation windows per clone datasheets; pair nuclear β-catenin with fractionation or IF co-localization with TCF7L2; control serum-driven TOPFlash artifacts.
- Active β-catenin vs total CTNNB1; nuclear/cytoplasmic fractionation
- p-LRP6 (e.g., Ser1490 per clone), membrane recruitment of DVL2
- TOPFlash/SuperTOPFlash; AXIN2, LEF1, MYC, CCND1 qPCR panels
- IF: nuclear β-catenin with TCF7L2 co-localization
- p-GSK3β (Ser9)—interpret alongside AKT and other inputs
3. Canonical vs non-canonical arms (summary)
| Arm | Representative nodes | Typical readouts | Notes |
|---|---|---|---|
| Canonical β-catenin | FZD, LRP5/6, DVL, APC–AXIN–GSK3, CTNNB1, TCF/LEF | TOPFlash; AXIN2; nuclear β-catenin | Coupled to stem-cell niches, intestine, many cancers. |
| PCP / CE | VANGL, PRICKLE, CELSR, DAAM, Rho–ROCK | Polarity & migration (model-dependent) | May not raise nuclear β-catenin–TCF reporters. |
| Wnt/Ca²⁺, etc. | Ca²⁺ 动员、CAMK、NFAT 语境节点 | Ca²⁺ imaging; NFAT reporters | Disentangle stimuli when co-existing with canonical Wnt. |
4. Disease & model context
- Colorectal cancer & APC loss: Destroyosome dysfunction drives constitutive programs—map adenoma–carcinoma sequence vs MSI status.
- HCC CTNNB1-mutant subsets: Hotspot mutations alter degradation phospho-sites; pair with immune context.
- Bone development & sclerosteoses: LRP5/6 and SOST-related biology in bone remodeling.
- Fibrosis & EMT crosstalk: Read alongside TGF-β/Smad with SNAIL/matrix genes—nuclear β-catenin ≠ reporter activity.
Wnt/β-catenin–related antibodies (curated)
5. Product lines & on-site search
Primary & phospho antibodies
β-catenin (total/active epitopes), LRP6, DVL, Axin, APC, TCF7L2, p-GSK3β, EMT readouts—WB/IHC/IF/ChIP per clone.
Recombinant proteins & reporters
Recombinant WNT3A etc. for stimulation; reporter lines need copy/integration QC.
Small-molecule tool compounds
Secretion blockers, GSK3 inhibitors, TCF–β-catenin interface disruptors—research use; safety/compliance.
6. Inhibitors & tool compounds (summary)
For research use; follow SOP, datasheets, and ethics. Some agents are toxic or regulated—compliant labs only.
PORCN inhibitor blocking Wnt palmitoylation/secretion.
Blocks Wnt secretion steps (Porcupine-dependent contexts).
TNKS1/2 inhibition—Axin stabilization, favors destruction-complex activity.
Disrupt β-catenin–TCF interface—tool compounds, limited specificity.
GSK3α/β inhibitor—common in stem-cell models; mind off-targets.
Weak GSK3 tool; dose window and ionic effects coexist.
7. Pathway schematic
- Wnt engages FZD + LRP5/6 and cytosolic regulators
- Destruction complex dampened → CTNNB1 stabilization
- β-catenin enters nucleus with TCF/LEF for targets
- Pair adherens pools & non-canonical arms with separate readouts
8. Pathway biology overview
Wnt/β-catenin sits at the hub of patterning, regeneration, and stemness; in cancer and chronic inflammation it often shares programs with TGF-β, MAPK, NF-κB, etc. Mechanistic claims should bridge membrane initiation (LRP6 phosphorylation stripes), cytosolic degradation control, and chromatin occupancy—and state whether models are cell lines, organoids, or transgenic animals.
- Intestinal crypt: RSPO–LGR–RNF43/ZNRF3 couples to stem programs
- Tumor heterogeneity: CTNNB1 vs APC subsets differ in immune/therapy context
9. Related pathways on this site
10. External databases & modification resources
- KEGG: hsa04310 Wnt signaling pathway
- Reactome: Signaling by WNT
- WikiPathways (search: Wnt)
- PhosphoSitePlus (CTNNB1, LRP6, GSK3 sites, etc.)
11. References
Reviews & framing
- • Nusse R, Clevers H. (2017). Cell. 169(6):985–999.
- • MacDonald BT, Tamai K, He X. (2009). Dev Cell. 17(1):9–26.
Cancer & therapeutic targeting
- • Clevers H, Nusse R. (2012). Cell. 149(6):1198–1208.
- • Zhan T, Rindtorff N, Boutros M. (2017). Nat Rev Cancer. 17(8):432–449.
Stem cells & tissue renewal
- • Clevers H, Loh KM, Nusse R. (2014). Science. 346(6208):1248012.